Table 1.
Current clinical trials of curcumin and resveratrol.
| Title | Design/phase | Intervention | Primary endpoint | Identifier |
|---|---|---|---|---|
| Study Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Colon Cancer Tissue | Phase I | Arm 1: curcumin alone Arm 2: curcumin with plant exosomes Arm 3: no treatment |
To estimate the effect of a fixed concentration of curcumin when delivered by plant exosomes compared to oral tablets of curcumin alone | NCT01294072 |
| Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci) | Phase II | Patients receive 1 of 2 doses of oral curcumin once daily | To determine mean percentage change from baseline in prostaglandin E2 (PGE2) within ACF pre and post 30 days of curcumin administration at a specified dose | NCT00365209 |
| Curcumin for the Chemoprevention of Colorectal Cancer | Phase II | 4 g curcumin daily for 4 months or placebo | Cellular proliferation and apoptosis in the colonic mucosa and COX-2 expression and activity | NCT00118989 |
| Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP) | Randomized double blind placebo controlled trial | Curcumin 2 pills twice per day or placebo 2 pills twice per day for 12 months | To determine the tolerability and efficacy of curcumin to regress intestinal adenomas by measuring duodenal and colorectal/ileal polyp number, and polyp size in patients with FAP | NCT00927485 |
| Curcumin in Treating Patients With Familial Adenomatous Polyposis | Randomized double blind placebo controlled trial | Curcumin 2 pills per day or placebo 2 pills per day for 12 months | To determine the tolerability and efficacy of curcumin to regress intestinal adenomas by measuring duodenal and colorectal/ileal polyp number, and polyp size in FAP patients | NCT00641147 |
| Curcumin Biomarkers | Phase I | 4 g curcumin C3 tablets daily for 30 days | To identify genes that are modified by curcumin that could be used as biomarkers in future chemoprevention studies. The study will also evaluate tolerability and toxicity | NCT01333917 |
| Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery | Phase I | Patients with colorectal adenocarcinomas receive resveratrol for days 1 to 8 and on day 9 undergo colorectomy. Tumor biopsy will be retrieved | To study the side effects and best dose of resveratrol in treating patients with colorectal cancer that can be removed by surgery | NCT00433576 |